Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01769963 · ClinicalTrials.gov registry record · NA

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

A NA study of Chronic Kidney Disease, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT01769963 is a NA study of Chronic Kidney Disease that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01769963, a NA study of Chronic Kidney Disease, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to learn more about how advanced glycation end-products can affect insulin resistance, inflammation and blood vessel health in people with kidney disease.

Conditions Studied

Interventions

  • OTHER Research diet

Study Locations (1)

Alabama

  • University of Alabama - Birmingham

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2012-04
Est. Completion 2014-02
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT01769963

The ClinicalTrials.gov registry entry for NCT01769963 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Research diet is the first listed.

NCT01769963 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT01769963 about?

NCT01769963 is a clinical study titled "Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease". The purpose of the study is to learn more about how advanced glycation end-products can affect insulin resistance, inflammation and blood vessel health in people with kidney disease.

What is the current status of trial NCT01769963?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2012-04. Estimated completion is 2014-02.

What conditions does trial NCT01769963 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT01769963?

The interventions under investigation include: Research diet (OTHER).

Who is sponsoring clinical trial NCT01769963?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01769963 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.